GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Clinical Investigation

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2362.2004.01381.xPMID 15305887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction.

  2013cited by this paper
• Gliclazide Modified Release

  2012cited by this paper
• Highlights of the 2003 Clinical Practice Guidelines for the prevention and management of diabetes in Canada.

  2004cited by this paper
• Guidelines for computer modeling of diabetes and its complications

  2004cited by this paper
• Standards of medical care in diabetes.

  2004cited by this paper
• Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy

  2003cited by this paper
• The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

  2003cited by this paper
• Hypoglycemia in diabetes.

  2003cited by this paper
• Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia

  2003cited by this paper
• Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects.

  2003cited by this paper
• Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

  2003cited by this paper
• The difficult question of sex: the mating game.

  2002cited by this paper
• Hypoglycaemia unawareness and the brain

  2002cited by this paper
• Glimepiride block of cloned β‐cell, cardiac and smooth muscle KATP channels

  2001cited by this paper
• Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels.

  2001cited by this paper
• Hypoglycaemia and cognitive function in diabetes.

  2001cited by this paper
• Acute hypoglycemia in humans causes attentional dysfunction while nonverbal intelligence is preserved.

  2001cited by this paper
• Hypoglycaemia and cognitive function in diabetes.

  2001cited by this paper
• Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study.

  2000cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)

  1999cited by this paper
• A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999.

  1999cited by this paper
• Differential sensitivity of beta-cell and extrapancreatic KATP channels to gliclazide

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Glimepiride

  1998cited by this paper
• Standards of Medical Care for Patients With Diabetes Mellitus

  1998cited by this paper
• Impact of Dosage Frequency on Patient Compliance

  1997cited by this paper
• Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM

  1997cited by this paper
• Rates of hypoglycemia in users of sulfonylureas.

  1997cited by this paper
• Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment

  1996cited by this paper
• Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations

  1996cited by this paper
• Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.

  1996cited by this paper
• Glibenclamide vs Gliclazide in Type 2 Diabetes of the Elderly

  1994cited by this paper
• Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function.

  1992cited by this paper
• Effects of glimepiride and glibenclamide on insulin and glucagon secretion by the perfused rat pancreas.

  1991cited by this paper
• Symptomatic Hypoglycemia in NIDDM Patients Treated With Oral Hypoglycemic Agents

  1989cited by this paper

• The valuable effects of Anzer bee products against the gliclazide-induced damage on human cell viability

  2026cites this paper
• Efficacy and Safety of Gliclazide versus Glimepiride in T2DM Patients: A Systematic Review

  2025influential citation
• Gliklazid – a szulfonilurea csoport preferálandó származéka

  2025cites this paper
• Taking a Closer Look at Gliclazide – Benefits Beyond Glycemic Control

  2025cites this paper
• Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

  2025cites this paper
• Risk Factors for Sarcopenia in Women with Type 2 Diabetes and the Effects of Metformin: A Cross-Sectional Study of 7,731 Patients from the UK Biobank

  2025cites this paper
• Optimizing Type 2 Diabetes Management: The Efficacy and Safety of Gliclazide in Clinical Practice

  2025cites this paper
• Outcomes of People with Type 2 Diabetes using Sulfonylureas versus Other Non-Insulin Antidiabetic Agents during Ramadan: The Diabetes and Ramadan (DaR) Global Surveys

  2025cites this paper
• Comprehensive management of polypharmacy in older patients with diabetes

  2024cites this paper
• Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review

  2024influential citation
• Current Treatment Options for Diabetic Retinal Disease

  2024cites this paper
• Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study

  2024cites this paper
• The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus

  2024cites this paper
• Optimal dosing of gliclazide—A model‐based approach

  2023influential citation
• Use of Classes of Antihyperglycemic Agents in People With Type 2 Diabetes Based on Level of Estimated Glomerular Filtration Rate.

  2023cites this paper
• A Review on Invitro Evolution of Glimepiride Tablets

  2023cites this paper
• 2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes

  2023cites this paper
• The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR

  2023cites this paper
• Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach

  2023influential citation
• Tratamiento de la diabetes mellitus tipo 2 en personas de edad avanzada o frágiles. Actualización 2022 del documento de consenso 2018 «Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano»

  2022cites this paper
• Evaluating gliclazide for the treatment of type 2 diabetes mellitus

  2022cites this paper
• KCNQ1 rs2237895 polymorphism is associated with the therapeutic response to sulfonylureas in Iranian type 2 diabetes mellitus patients

  2022cites this paper
• A gliklazid MR helye a 2-es típusú diabetes jelen antidiabetikus kezelésében

  2022cites this paper
• Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register

  2022cites this paper
• Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review.

  2022cites this paper
• Management of Diabetes in the Elderly

  2022cites this paper
• A Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide Modified Release during Fasting in Gulf Cooperation Council Countries: An Analysis from the International DIA-RAMADAN Study

  2022cites this paper
• Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies

  2022cites this paper
• Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis

  2022cites this paper
• Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas

  2021cites this paper
• Les sulfamides hypoglycémiants gardent toujours une place dans le traitement du diabète de type 2 en 2021. Les points forts du dossier des sulfamides hypoglycémiants

  2021cites this paper
• Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR During Fasting: DIA-RAMADAN

  2021cites this paper
• Sulphonylureas in the management of type 2 diabetes: To be or not to be?

  2021cites this paper
• Diabetes and Frail Older Patients: Glycemic Control and Prescription Profile in Real Life

  2021cites this paper
• The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function

  2021cites this paper
• ADVANCE research 20 years later

  2021cites this paper
• Real-world experience of treatment individualization based on fixed-dose combination of gliclazide extended release+ metformin extended release in type 2 diabetes mellitus

  2021cites this paper
• The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India

  2021cites this paper
• Literature review: drug and alcohol-induced hypoglycaemia

  2021cites this paper
• Role of Gliclazide in Safely Navigating Type 2 Diabetes Mellitus Patients Towards Euglycemia: Expert opinion from India

  2021cites this paper
• The role of sulfonylureas in the treatment of type 2 diabetes

  2021cites this paper
• The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathy—A Review

  2021cites this paper
• The Place of Sulfonylureas in Guidelines: Why Are There Differences?

  2020cites this paper
• The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy

  2020cites this paper
• Diabetes and Genetics: A Relationship Between Genetic Risk Alleles, Clinical Phenotypes and Therapeutic Approaches.

  2020cites this paper
• Latest Evidence on Sulfonylureas: What’s New?

  2020cites this paper
• Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations

  2020cites this paper
• Existe-t-il encore une place pour les sulfamides hypoglycémiants dans le traitement du diabète de type 2 en 2021 ?

  2020cites this paper
• Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study

  2020cites this paper
• [Blood-glucose control in eldely patients with type 2 diabetes. Interventions to avoid risks].

  2020cites this paper
• Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel

  2020cites this paper
• Radix pseudostellariae of Danzhi Jiangtang capsule relieves oxidative stress of vascular endothelium in diabetic macroangiopathy

  2020cites this paper
• Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives

  2020cites this paper
• Sulfonylureas in the Treatment of Type 2 Diabetes Mellitus: A Fresh Look and New Insights

  2020cites this paper
• Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus

  2020cites this paper
• A lion in the room: Has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas?

  2020cites this paper
• Features of postoperative therapy in patients with type ІІ diabetes

  2020cites this paper
• Glucodynamics and glucocracy in type 2 diabetes mellitus: clinical evidence and practice-based opinion on modern sulfonylurea use, from an International Expert Group (South Asia, Middle East & Africa) via modified Delphi method

  2020cites this paper
• A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN.

  2020cites this paper
• Comparative effectiveness of gliclazide modified release versus sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes

  2020cites this paper
• Synthesis of Sulfonated Dihydrofuropyrazoles Derivatives as Antimicrobial Active Agents

  2019cites this paper
• A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019

  2019cites this paper
• Diabetic Pharmacotherapies in Kidney Disease

  2019cites this paper
• Quantification of Insulin Action in Human Subjects

  2019cites this paper
• 3-((Hetera)cyclobutyl)azetidines, "Stretched" Analogues of Piperidine, Piperazine, and Morpholine: Advanced Building Blocks for Drug Discovery.

  2019cites this paper
• Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?

  2019cites this paper
• Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study.

  2019cites this paper
• Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment

  2019cites this paper
• The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm

  2019cites this paper
• Le diabète chez les personnes âgées Comité d’experts des Lignes directrices de pratique clinique de Diabète Canada

  2019cites this paper
• Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes

  2019cites this paper
• Pharmacological Therapy of Diabetes in the Elderly

  2019cites this paper
• Attitude and safety of patients with diabetes observing the Ramadan fast.

  2019cites this paper
• Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano

  2018cites this paper
• Diabetic patient in palliative care

  2018cites this paper
• Managing diabetes and liver disease association.

  2018cites this paper
• Treatment of type 2 diabetes mellitus in elderly patients

  2018cites this paper
• Long-Term Patterns of Antidiabetic Medication Use in Patients with Type 2 Diabetes

  2018cites this paper
• Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies

  2018cites this paper
• Diabetes in Older People.

  2018cites this paper
• The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.

  2018cites this paper
• Actualización del efecto de los antihiperglicemiantes en la función renal en diabetes mellitus tipo 2

  2018cites this paper
• Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force

  2018influential citation
• Treatment of type 2 diabetes mellitus in elderly patients.

  2018cites this paper
• Do sulphonylureas still have a place in clinical practice?

  2018cites this paper
• Preliminary Study on the Formulation of Syariah Compliant Generic Sustained Release Gliclazide Tablet Using Xanthan Gum

  2018cites this paper
• Diabetes in the elderly

  2017cites this paper
• Epidemiologic Surveillance of Glycemic Response to a Scored, Breakable, Extended Release, Fixed Dose Combination of Gliclazide and Metformin in Persons with Type 2 Diabetes.

  2017cites this paper
• Diabetes and Ramadan: A concise and practical update

  2017cites this paper
• MACROVASCULAR COMPLICATIONS IN DIABETES ( VR ARODA AND A GETANEH , SECTION EDITORS ) The Infamous , Famous Sulfonylureas and Cardiovascular Safety : Much Ado About Nothing ?

  2017cites this paper
• Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.

  2017influential citation
• Synchronized Fast SPE and UFLC Methods for the Analyses of Eight Antidiabetic Drugs in Human Plasma.

  2017cites this paper
• Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events

  2017cites this paper
• Diabetes Mellitus and Ramadan: Physiopathological, Clinical and Therapeutic Aspects

  2017cites this paper
• Ramadan fasting in diabetes-exercise in problem-solving.

  2017cites this paper
• Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial

  2017cites this paper
• Protective effects of Danggui Buxue Tang on renal function, renal glomerular mesangium and heparanase expression in rats with streptozotocin-induced diabetes mellitus.

  2016cites this paper
• Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis.

  2016influential citation
• Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes

  2016cites this paper
• Is gliclazide a sulfonylurea with difference? A review in 2016

  2016cites this paper